White House denies reports Trump received Eli Lilly's unapproved obesity drug retatrutide through an FDA program.

A bombshell report about how a 79-year-old man got early access to a weight loss drug has all eyes on the president.

A report from STAT News said Eli Lilly and the FDA gave a 79-year-old man exclusive access to the drug after a request for it was made in April.

A stunning report reveals the president may have gotten an early access to an obesity drug to treat major medical issues.

Questions are swirling over Donald Trump’s health after a bombshell report revealed a mystery man was getting unprecedented access to a weight-loss drug.

Compassionate use of retatrutide granted for someone with sleep apnea, pulmonary hypertension

The White House has denied that the application was filed on behalf of President Donald Trump.

A White House spokesman said theories that President Trump sought the drug were ‘baseless speculation’

The FDA let one 79-year-old take an experimental obesity drug. That sure sounds like the president, but let’s examine the evidence.

Un medio asegura que la farmacéutica Eli Lily facilitó el medicamento a un paciente con las características del mandatario

The FDA gave one well-connected 79-year-old early access to Eli Lilly’s new drug. Its sure sounds like the president, but let’s examine the evidence.

Stay up to date with notifications from The IndependentNotifications can be managed in browser preferences.AllNewsSportCultureLifestyleWhite House officials are denying that…

The White House denied that the single approval of Eli Lilly's highly-anticipated weight loss drug retatrutide was for Trump after a STAT report.

White House denies reports Trump received Eli Lilly's unapproved obesity drug retatrutide through an FDA program.

Trump faced fresh health speculation after reports linked him to an experimental drug and a viral video, but the White House denied the medication claim.